

Accenture Life Sciences

Rethink Reshape Restructure...for better patient outcomes

Great Expectations: Why Pharma Companies Can't Ignore Patient Services


High performance. Delivered.


Key findings from a survey of 2,000 patients in the United States



What do pharma CIO's think?

85% of pharma CIO's are interested in hearing about Patient Services





About this research ...

- Who: 2,000 respondents in the United States, 18 years or above, with annual household income of \$25K+, and currently taking a short-term medicine (e.g., antibiotics, or migraine medication), a long-term medicine (such as those for treatment of diabetes, or high blood pressure), or a lifestyle medicine (e.g., birth control pills, or erectile dysfunction therapies).
- What: perspectives on patient services, including information or education, financial assistance, reward programs, physician referrals, and nurse support.
- When: September and October, 2013


Is there an Industry Imperative?

There is a great deal of chatter about the industry shifting from products to services, but what do patients expect from pharma?



The vast majority of patients don't just want services—they expect them

Do pharmaceutical companies have a responsibility to provide services that complement their products?








And patients are willing to interact with pharma ...

When would you be most receptive to pharmaceutical companies contacting you?



64% are willing to provide personal information on their health in exchange for free information and services directed to them





3 Patients greatly value services when they get them

Comparison of Satisfaction







However, there are some significant gaps between the services patients want and those they are receiving.






Patients are proactive, digitally-enabled and continuously seek health-related services from a variety of channels and sources



68% of patients are online several hours a day and many prefer pharmaco's reach them through digital channels.



What are the implications?

Will this really change how pharma operates, and if so, how?



Hypothesis #1: Industry leaders will drive their success through a combination of both innovative medicines and high value services

Can patient services drive a tangible ROI or support improved health outcomes? What is the biggest challenge for pharma to realize these types of results?

Hypothesis #2: The expansion of patient services will create a need to unify the experience patients have over time and across services

How prepared is pharma to coordinate patient relationships and multiservice engagement? What will need to evolve to make this attainable (e.g. capabilities, partners, legal/compliance changes)





Hypothesis #3: There will be an increased interest & need for engagement with niche vendors for differentiated service offerings in a rapidly evolving market of disruptive technologies

What changes are required for pharma to become more flexible and dynamic in leveraging unique technologies for patient services?

Hypothesis #4: Patients
intuitively desire
reimbursement support, but
this is only one element of a
broader need to raise the
game in managing brand value
in terms of price-tooutcome

Is there a role for patient services to support the growing industry challenge of demonstrating patient outcomes to obtain approval and reimbursement status?



Hypothesis #5: While there are data privacy and compliance challenges associated with patient services, leading companies will find ways to approach this to optimize their engagement with patients responsibly



How must pharma adapt to be successful meeting patient expectations, given the constraints and risks?

Accenture Patient Care Business Services

Tony Romito Managing Director anthony.r.romito@accenture.com